News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Roche Holding AG, Biogen Idec, Inc. (Massachusetts) Suspends Arthritis Treatment Ocrelizumab After Deaths
March 8, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Swiss drugmaker Roche Holding AG (ROG.VX) and U.S.-listed Biogen Idec (BIIB.O) are suspending rheumatoid arthritis and lupus treatment ocrelizumab after it caused deaths, casting doubt over the drug's future.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Biogen
MORE ON THIS TOPIC
Obesity
Lilly’s Amylin Agonist Headed to Phase III After Eliciting up to 20% Weight Loss
November 6, 2025
·
3 min read
·
Heather McKenzie
IN PARTNERSHIP WITH PII
Thoughtful Tech: How Removing Technological Burdens Can Improve Clinical Trial Compliance and Patient Experience
November 6, 2025
·
1 min read
·
BioSpace Insights
FDA
Webinar: FDA in 2025: Navigating an Uncertain Regulatory Future
November 5, 2025
·
1 min read
·
Jef Akst
Podcast
Pfizer and Novo Battle Over Metsera, Tidmarsh Fights FDA Exit, UniQure and Sarepta Face Setbacks
November 5, 2025
·
1 min read
·
Heather McKenzie
